tools
Chai-2
AI protein-design model for generating de novo antibodies, nanobodies, miniprotein binders, and epitope-specific designs.
Chai-2 generates protein binders from target structures or sequences. It supports antibody formats including mAbs, VH-VL, VHH, scFvs, nanobodies, and miniproteins, with controls for epitopes, antigen states, chemical modifications, species specificity, and cross-reactivity.
It is intended for academic and commercial drug-discovery organizations. Access requires an application; academic access is described as limited and non-commercial. No public self-serve pricing was listed.
Features
- Designs de novo antibodies and miniprotein binders
- Supports mAbs, VH-VL, VHH, scFv, and nanobody formats
- Uses public or private target structures and supplied sequences
- Targets selected, small, buried, or non-immunogenic epitopes
- Handles ligands and post-translational modifications such as glycans
- Controls species or ortholog specificity and cross-reactivity
- Targets membrane proteins and specific antigen states
Use cases
- Design antibodies against challenging or novel protein targets
- Target a defined epitope on a protein structure
- Generate binders for membrane proteins and GPCRs
- Engineer agonist or antagonist antibodies against a target state
- Design binders around ligands or post-translational modifications
Pros
Cons
Latest updates
- Drug-like antibody design against challenging targets with atomic precision (Chai-2)
Moving de novo antibody design past binding and closer to therapeutics.
- Introducing Chai-2: Zero-shot antibody design in a 24-well plate (Chai-2)
Chai-2 models achieve double digit hit rates in de novo antibody design.
- Chai Discovery Unveils Chai-2 Breakthrough, Achieving Fully De Novo Antibody Design With AI (Chai-2)
Unveils Chai-2 for fully de novo antibody design with AI.
- Introducing Chai-1: Decoding the molecular interactions of life (Chai-1)
Model for molecular structure prediction across tasks relevant to drug discovery.
Pricing
- Prices checked
- 2026-10-26
- Read
- by web search
Chai-2 Access (Commercial)
Price on request
- De novo antibody and miniprotein design
- Double-digit hit rates for antibodies (>10%)
- High success rates for miniproteins (>50%)
- Any antibody format (mAbs, VH-VL/VHH, etc.)
- Target any epitope or antigen state
- Commercial organizations: schedule a call via access form
Chai-2 Access (Academic)
Price on request
- Limited non-commercial use
- De novo antibody and miniprotein design
- Double-digit hit rates for antibodies (>10%)
- High success rates for miniproteins (>50%)
- Register interest via access form for early access